Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01188928 · ClinicalTrials.gov registry record · Phase 3
LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs)
A Phase 3 study, sponsored by LEO Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,152
- Enrollment target
NCT01188928 is a Phase 3 study that has completed, run by LEO Pharma. The registered enrollment target is 1,152 participants.
The verdict
NCT01188928, a Phase 3 study, has completed, sponsored by LEO Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,152 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the efficacy and safety of Calcipotriol 50 Mcg/g Plus Betamethasone 0.5 mg/g (as Dipropionate) Topical Suspension with the active components when used individually as monotherapy in the topical suspension vehicle (betamethasone dipropionate in the topical suspension vehicle, calcipotriol in the topical suspension vehicle) and with the topical suspension vehicle alone in the treatment of psoriasis vulgaris on the non-scalp regions of the body (trunk and/or limbs) in a large phase 3 study. This comparison will ensure a more informed assessment of the benefit/risk ratio of Calcipotriol 50 Mcg/g Plus Betamethasone 0.5 mg/g (as Dipropionate) Topical Suspension while also establishing the optimal treatment duration in psoriasis vulgaris on the non-scalp regions of the body (trunk and/or limbs).
Interventions
- DRUG Calcipotriene
- DRUG Calcipotriol plus betamethasone
- DRUG Betamethasone-17,21-dipropionate
- DRUG Topical suspension vehicle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,152 participants |
| Start Date | 2010-09 |
| Est. Completion | 2011-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01188928
The ClinicalTrials.gov registry entry for NCT01188928 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,152 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LEO Pharma, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Calcipotriene is the first listed.
NCT01188928 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01188928 about?
NCT01188928 is a clinical study titled "LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs)". The purpose of this study is to compare the efficacy and safety of Calcipotriol 50 Mcg/g Plus Betamethasone 0.5 mg/g (as Dipropionate) Topical Suspension with the active components when used individually as monotherapy in the topical suspension vehicle (betamethasone dipropionate in the topical susp...
What is the current status of trial NCT01188928?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,152 participants. The study started on 2010-09. Estimated completion is 2011-03.
What interventions are being tested in trial NCT01188928?
The interventions under investigation include: Calcipotriene (DRUG), Calcipotriol plus betamethasone (DRUG), Betamethasone-17,21-dipropionate (DRUG), Topical suspension vehicle (DRUG).
Who is sponsoring clinical trial NCT01188928?
This trial is sponsored by LEO Pharma, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.